Acurx Pharmaceuticals, Inc. (ACXP )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ACXP
- Company Acurx Pharmaceuticals, Inc.
- Price $1.96
- Changes Percentage 44.81
- Change 0.605
- Day Low $1.37
- Day High $2.04
- Year High $21
- Year Low $1.33
- Market Cap $3,098,632
- Price Avg 50 EMA (D) $2.3
- Price Avg 200 EMA (D) $5.15
- Exchange NASDAQ
- Volume 2,180,818
- Average Volume 157,135
- Open $1.4
- Previous Close $1.35
- EPS -8.18
- PE -0.24
- Earnings Announcement 2026-03-13 12:30:00
- Shares Outstanding $1,584,978
Company brief: ACURX PHARMACEUTICALS, INC. (ACXP )
- Healthcare
- Biotechnology
- Mr. David P. Luci CPA, Esq., J.D.
- https://www.acurxpharma.com
- US
- N/A
- 06-25-2021
- US00510M1045
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
ACXP Corporation News
Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
prnewswire.com -- Acurx's Program in the Broader CDI Patient Population is Ready to Advance to Phase 3 International Clinical Trials Acurx is launching a ground-breaking clinical trial with ibezapolstat in patients wit...